参考文献/References:
[1] Liu X, Rao S, Wang J. Intravenous thrombolysis in combination with mild hypothermia therapy in the treatment of acute cerebral infarction[J]. Pakistan Journal of Medical Sciences, 2019, 35(4):1161-1166.
[2] Gauberti M, Potzeha F, Vivien D, et al. Impact of bradykinin Generation during thrombolysis in ischemic stroke[J]. Frontiers in Medicine, 2018, 5(7): 195.
[3] Zhang J, Yang Y, Sun H, et al. Hemorrhagic transformation after cerebral infarction: current concepts and challenges[J]. Ann Transl Med, 2014, 2(8): 81.
[4] Bang OY, Saver JL, Kim SJ, et al. Collateral flow averts hemorrhagic transformation after endovascular therapy for acute ischemic stroke[J]. Stroke, 2011, 42(8): 2235-2239.
[5] Wang L, Song Q, Wang C, et al. Neutrophil to lymphocyte ratio predicts poor outcomes after acute ischemic stroke: A cohort study and systematic review[J]. J Neurol Sci, 2019, 406(11): 116445.
[6] Shi K, Zou M, Jia DM, et al. tPA mobilizes immune cells that exacerbate hemorrhagic transformation in stroke[J]. Circ Res, 2021, 128(1): 62-75.
[7] Jickling GC, Liu DZ, Stamova B, et al. Hemorrhagic transformation after ischemic stroke in animals and humans[J]. J Cereb Blood Flow Metab, 2014, 34(2): 185-199.
[8] García-Culebras A, Palma-Tortosa S, Moraga A, et al. Toll-Like receptor 4 mediates hemorrhagic transformation after delayed tissue plasminogen activator administration in in situ thromboembolic stroke[J]. Stroke, 2017, 48(6): 1695-1699.
[9] Liu DL, Hong Z, Jy L, et al. Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP(peroxiredoxin 1)clearance[J]. J Neuroinflammation, 2021, 18(1): 143.
[10] Park CH, Shin TK, Lee HY, et al. Matrix metalloproteinase inhibitors attenuate neuroinflammation following focal cerebral ischemia in mice[J]. Korean J Physiol Pharmacol, 2011, 15(2): 115-122.
[11] Ma G, Pan Z, Kong L, et al. Neuroinflammation in hemorrhagic transformation after tissue plasminogen activator thrombolysis: Potential mechanisms, targets, therapeutic drugs and biomarkers[J]. Int Immunopharmacol, 2021, 90(7): 107216.
[12] Jin R, Yang G, Li G. Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: critical role of matrix metalloproteinases and tissue-type plasminogen activator[J]. Neurobiol Dis, 2010, 38(3): 376-385.
[13] Liu J, Jin X, Liu KJ, et al. Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage[J]. J Neurosci, 2012, 32(9): 3044-3057.
[14] Hafez S, Abdelsaid M, El-Shafey S, et al. Matrix metalloprotease 3 exacerbates hemorrhagic transformation and worsens functional outcomes in hyperglycemic stroke[J]. Stroke, 2016, 47(3): 843-851.
[15] Lapchak PA, Chapman DF, Zivin JA. Metalloproteinase inhibition reduces thrombolytic(tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke[J]. Stroke, 2000, 31(12): 3034-3040.
[16] Suzuki Y, Nagai N,Umemura K. Novel situations of endothelial injury in stroke--mechanisms of stroke and strategy of drug development:intracranial bleeding associated with the treatment of ischemic stroke:thrombolytic treatment of ischemia-affected endothelial cells with tissue-type plasminogen activator[J]. J Pharmacol Sci, 2011, 116(1): 25-29.
[17] Hafez S, Abdelsaid M, Fagan SC, et al. Peroxynitrite-Induced tyrosine nitration contributes to matrix metalloprotease-3 activation: relevance to hyperglycemic ischemic brain injury and tissue plasminogen activator[J]. Neurochem Res, 2018, 43(2): 259-266.
[18] Kong L, Ma Y, Wang Z, et al. Inhibition of hypoxia inducible factor 1 by YC-1 attenuates tissue plasminogen activator induced hemorrhagic transformation by suppressing HMGB1/TLR4/NF-κB mediated neutrophil infiltration in thromboembolic stroke rats[J]. Int Immunopharmacol, 2021, 94(5): 107507.
[19] Brennan AM, Suh SW, Won SJ, et al. NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation[J]. Nat Neurosci, 2009, 12(7): 857-863.
[20] Sun MS, Jin H, Sun X, et al. Free radical damage in Ischemia-Reperfusion injury: an obstacle in acute ischemic stroke after revascularization therapy[J]. Oxid Med Cell Longev, 2018,(1): 3804979.
[21] Chen HS, Chen X, Li WT, et al. Targeting RNS/caveolin-1/MMP signaling cascades to protect against cerebral ischemia-reperfusion injuries: potential application for drug discovery[J]. Acta Pharmacol Sin, 2018, 39(5): 669-682.
[22] Jia W, Lu RC, Martin TA, et al. The role of claudin-5 in blood-brain barrier(BBB)and brain metastases(Review)[J]. Mol Med Rep, 2014, 9(3): 779-785.
[23] Zhang ZG, Zhang L, Jiang Q, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain[J]. J Clin Invest, 2000, 106(7): 829-838.
[24] Yamashita T, Kamiya T, Deguchi K, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain[J]. J Cereb Blood Flow Metab, 2009, 29(4): 715-725.
[25] Jiang X, Yi Y. Hemorrhagic transformation induced by acute hyperglycemia in a rat model of transient focal ischemia[J]. Acta Neurochir Suppl, 2011, 111(111): 49-54.
[26] Yuan C, Chen S, Ruan Y, et al. The stress hyperglycemia ratio is associated with hemorrhagic transformation in patients with acute ischemic stroke[J]. Clin Interv Aging, 2021, 16(3): 431-442.
[27] Pires PW, Dams RC, Matin N, et al. The effects of hypertension on the cerebral circulation[J]. Am J Physiol Heart Circ Physiol, 2013, 304(12): H1598-H1614.
[28] Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis retrospective analysis from safe implementation of thrombolysis in Stroke-International stroke thrombolysis register(SITS-ISTR)[J]. Stroke, 2009, 40(7): 2442-2449.
[29] Cheng HR, Chen YB, Zeng YY, et al. Hemostasis functions are associated with hemorrhagic transformation in non-atrial fibrillation patients: a case-control study[J]. BMC Neurol, 2021, 21(1): 36.
[30] Wang R, Zeng J, Wang F, et al. Risk factors of hemorrhagic transformation after intravenous thrombolysis with rt-PA in acute cerebral infarction[J]. QJM, 2019, 112(5): 323-326.
[31] Dourado SF, Cal?da A, Aguiar DD, et al. Mean platelet volume is a prognostic marker in acute ischemic stroke patients treated with intravenous thrombolysis[J]. J Stroke Cerebrovasc Dis, 2021, 30(6): 105718.
[32] Tan S, Wang D, Liu M, et al. Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis[J]. J Neurol, 2014, 261(5): 905-912.
[33] Tu HT, Campbell BC, Christensen SA, et al. Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation[J]. International Journal of Stroke, 2015, 10(4): 534-540.
[34] Terruso V, D’amelio M, Di Benedetto N, et al. Frequency and determinants for hemorrhagic transformation of cerebral infarction[J]. Neuroepidemiology, 2009, 33(3): 261-265.
[35] Charidimou A, Pasi M, Fiorelli M, et al. Leukoaraiosis, cerebral hemorrhage, and outcome after intravenous thrombolysis for acute ischemic stroke a Meta-Analysis(v1)[J]. Stroke, 2016, 47(9): 2364-2372.
[36] Jickling GC, Ander BP, Stamova B, et al. RNA in blood is altered prior to hemorrhagic transformation in ischemic stroke[J]. Ann Neurol, 2013, 74(2): 232-240.
[37] Nagaraja N, Tasneem N, Shaban A, et al. Cerebral microbleeds are an Independent predictor of hemorrhagic transformation following intravenous alteplase administration in acute ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2018, 27(5): 1403-1411.
[38] Ge WQ, Chen J, Pan H, et al. Analysis of risk factors increased hemorrhagic transformation after acute ischemic stroke[J]. J Stroke Cerebrovasc Dis, 2018, 27(12): 3587-3590.
[39] Kidwell CS, Latour L, Saver JL, et al. Thrombolytic toxicity: blood brain barrier disruption in human ischemic stroke[J]. Cerebrovasc Dis, 2008, 25(4): 338-343.
[40] Scalzo F, Alger JR, Hu X, et al. Multi-center prediction of hemorrhagic transformation in acute ischemic stroke using permeability imaging features[J]. Magn Reson Imaging, 2013, 31(6): 961-969.
[41] Suh CH, Jung SC, Cho SJ, et al. Perfusion CT for prediction of hemorrhagic transformation in acute ischemic stroke: a systematic review and meta-analysis[J]. Eur Radiol, 2019, 29(8): 4077-4087.
[42] Inzitari D, Giusti B, Nencini P, et al. MMP9 variation after thrombolysis is associated with hemorrhagic transformation of lesion and death[J]. Stroke, 2013, 44(10): 2901-2903.
[43] Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke[J]. Stroke, 2007, 38(9): 2491-2495.
[44] Choi KH, Park MS, Kim JT, et al. The serum ferritin level is an important predictor of hemorrhagic transformation in acute ischaemic stroke[J]. European Journal of Neurology, 2012, 19(4): 570-577.
[45] Wang S, Ma F, Huang L, et al. Dl-3-n-Butylphthalide(NBP): A promising therapeutic agent for ischemic stroke[J]. CNS Neurol Disord Drug Targets, 2018, 17(5): 338-347.
[46] Yamaguchi T, Awano H, Matsuda H, et al. Edaravone with and without.6 mg/kg Alteplase within 4.5 Hours after Ischemic Stroke: A Prospective Cohort Study(PROTECT4.5)[J]. J Stroke Cerebrovasc Dis, 2017, 26(4): 756-765.
[47] Qin T, Castillo J. Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model[J]. Stroke, 2013, 44(2): 505-511.
[48] Tian DC, Shi K, Zhu Z, et al. Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow[J]. Ann Neurol, 2018, 84(5): 717-728.
[49] Li M, Zhang Z, Sun W, et al. 17β-estradiol attenuates breakdown of blood-brain barrier and hemorrhagic transformation induced by tissue plasminogen activator in cerebral ischemia[J]. Neurobiol Dis, 2011, 44(3): 277-283.
[50] Nilgnenol, Nazrolu M. Melatonin reduces traumatic brain injury-induced oxidative stress in the cerebral cortex and blood of rats[J]. Neural Regen Res, 2014, 9(11): 1112-1116.
[51] Shi L, Liang F, Zheng J, et al. Melatonin regulates apoptosis and autophagy via ROS-MST1 pathway in subarachnoid hemorrhage[J]. Front Mol Neurosci, 2018, 11(3): 93.
[52] Shao A, Gao S, Wu H, et al. Melatonin ameliorates hemorrhagic transformation via suppression of ROS-Induced NLRP3 activation after cerebral ischemia in hyperglycemic rats[J]. Oxid Med Cell Longev, 2021,(3): 6659282.
[53] Campbell B, Mitchell PJ, Churilov L, et al. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke[J]. N Engl J Med, 2018, 378(17): 1573-1582.
[54] Novotny V, Assmus J. Tenecteplase versus alteplase for management of acute ischaemic stroke(NOR-TEST):a phase 3,randomised,open-label,blinded endpoint trial[J]. Lancet Neurol, 2017, 16(10): 781-788.
[55] Campbell B, Mitchell PJ, Churilov L, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial[J]. JAMA, 2020, 323(13): 1257-1265.